Literature DB >> 8520751

Long-term circadian effects of salmeterol in asthmatic children treated with inhaled corticosteroids.

G G Meijer1, D S Postma, P G Mulder, W M van Aalderen.   

Abstract

The present study was set up to investigate whether salmeterol in children with asthma already treated with inhaled corticosteroids (ICS) leads to a sustained bronchodilator effect and decreased bronchial responsiveness, both during the day and night. Furthermore, we investigated whether cessation of salmeterol leads to a rebound increase in bronchial responsiveness. Forty children with asthma (aged 7-15 yrs) using ICS participated in a randomized, double-blind, parallel study. They received either twice daily 50 micrograms salmeterol or placebo. FEV1 and provocative concentration of methacholine that caused a 20% fall in FEV1 (PC20) were measured at 4:00 P.M. and 4:00 A.M. at baseline and after 16 wk. The same measurements were performed at 4:00 P.M. at 8 h after the first dose, and after 1 and 8 wk. After cessation of the study drug, FEV1 and PC20 were measured at 12 and 20 h and after 1 wk. Overall mean FEV1 from 1 to 16 wk of treatment was significantly higher in the salmeterol group than in the placebo group (difference, 4.9 +/- 2.0%, p = 0.01). Evolution in time of FEV1 did not differ significantly between the two groups (p = 0.09). Overall mean PC20 from 1 to 16 wk of treatment was not significantly higher with salmeterol than with placebo (difference, 0.7 +/- 0.4 doubling dose [DD] p = 0.07); evolution in time of PC20 did not differ significantly between the two groups (p = 0.58).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8520751     DOI: 10.1164/ajrccm.152.6.8520751

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  17 in total

Review 1.  Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma.

Authors:  E H Walters; J A Walters; P W Gibson
Journal:  Cochrane Database Syst Rev       Date:  2002

Review 2.  Antagonism of long-acting beta2-adrenoceptor agonism.

Authors:  Brian J Lipworth
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

Review 3.  Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma.

Authors:  J C Adkins; D McTavish
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

4.  Pharmacotherapy--add-on therapies.

Authors: 
Journal:  CMAJ       Date:  2005-09-13       Impact factor: 8.262

Review 5.  Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma.

Authors:  Francine M Ducharme; Muireann Ni Chroinin; Ilana Greenstone; Toby J Lasserson
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

6.  Salmeterol in paediatric asthma.

Authors:  C Byrnes; S Shrewsbury; P J Barnes; A Bush
Journal:  Thorax       Date:  2000-09       Impact factor: 9.139

Review 7.  Treatment of childhood asthma: how do the available options compare?

Authors:  David Coghlan; Colin Powell
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 8.  Benefit-risk assessment of long-acting beta2-agonists in asthma.

Authors:  Catherine M Jackson; Brian Lipworth
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 9.  Long-acting beta 2-adrenoceptor agonists and exercise-induced asthma: lessons to guide us in the future.

Authors:  Sandra D Anderson; John D Brannan
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

Review 10.  Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children.

Authors:  Muireann Ni Chroinin; Ilana Greenstone; Toby J Lasserson; Francine M Ducharme
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.